Cohance Lifesciences Limited (NSE:COHANCE)

Market Cap	377.23B
Revenue (ttm)	11.98B
Net Income (ttm)	2.68B
Shares Out	382.57M
EPS (ttm)	10.45
PE Ratio	94.36
Forward PE	60.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	879,046
Average Volume	140,245
Open	970.00
Previous Close	986.05
Day's Range	899.00 - 979.85
52-Week Range	904.90 - 1,360.00
Beta	0.64
RSI	36.22
Earnings Date	Aug 8, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,193
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: COHANCE

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.